Ziresovir earns global recognition, boosting hope for young RSV patients and strengthening ArkBio’s innovative pipeline.

RSV is the leading pathogen of lower respiratory tract infections (LRTIs) in infants and young children globally, causing ...

Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...

Shifts in RSV testing methodology, which were accelerated by changes related to the COVID-19 pandemic, mirror shifts seen in ...

The treatment reduced the risk of hospitalization by 83% U.S. babies enjoyed better protection because treatment was prioritized for high-risk infants TUESDAY, May 6, 2025 (HealthDay News ...

Babies treated with nirsevimab had an 83% reduced risk of hospitalization due to RSV infection, researchers reported May 1 in The Lancet Child & Adolescent Health. The antibody treatment also ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

TUESDAY, May 6, 2025 (HealthDay News) -- Newborns can be effectively protected against respiratory syncytial virus (RSV) infection through the use of nirsevimab, a monoclonal antibody treatment ...